AI Article Synopsis

  • Alzheimer's disease (AD) shows variability in how patients respond to amyloid beta removal therapy, impacting individual treatment benefits.
  • A study utilized random forest models on the EMERGE trial to create an individual-level treatment response (ITR) score, highlighting significant differences in treatment effects among patients.
  • Findings revealed that the top 25% of responders had distinct characteristics, such as lower hippocampal volume and more advanced disease, suggesting that precision medicine approaches could enhance future AD research and treatment strategies.*

Article Abstract

Introduction: Alzheimer's disease (AD) is a neurological disorder with variability in pathology and clinical progression. AD patients may differ in individual-level benefit from amyloid beta removal therapy.

Methods: Random forest models were applied to the EMERGE trial to create an individual-level treatment response (ITR) score which represents individual-level benefit of high-dose aducanumab relative to the placebo. This ITR score was used to test the existence of heterogeneity in treatment effect (HTE).

Results: We found statistical evidence of HTE in the Clinical Dementia Rating-Sum of Boxes (CDR-SB;P =  0.034). The observed CDR-SB benefit was 0.79 points greater in the group with the top 25% of ITR score compared to the remaining 75% (P = 0.020). Of note, the highest treatment responders had lower hippocampal volume, higher plasma phosphorylated tau 181 and a shorter duration of clinical AD at baseline.

Discussion: This ITR analysis provides a proof of concept for precision medicine in future AD research and drug development.

Highlights: Emerging trials have shown a population-level benefit from amyloid beta (Aβ) removal in slowing cognitive decline in early Alzheimer's disease (AD). This work demonstrates significant heterogeneity of individual-level treatment effect of aducanumab in early AD. The greatest clinical responders to Aβ removal therapy have a pattern of more severe neurodegenerative process.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10917030PMC
http://dx.doi.org/10.1002/alz.13431DOI Listing

Publication Analysis

Top Keywords

individual-level treatment
12
amyloid beta
12
alzheimer's disease
12
itr score
12
precision medicine
8
heterogeneity individual-level
8
treatment response
8
beta removal
8
early alzheimer's
8
individual-level benefit
8

Similar Publications

Background: The initial theme of the PROGRESS framework for prognosis research is termed overall prognosis research. Its aim is to describe the most likely course of health conditions in the context of current care. These average group-level prognoses may be used to inform patients, health policies, trial designs, or further prognosis research.

View Article and Find Full Text PDF

Introduction: One of the key strategies to achieve the sustainable development goal by reducing maternal deaths below 70 per 100,000 is improving knowledge of obstetric danger signs (ODS). However, mothers' knowledge of ODS is low in general and very low in rural settings, regardless of local and national efforts in Ethiopia. Further, there is significant variation of ODS knowledge among women from region to region and urban/rural settings.

View Article and Find Full Text PDF

Purpose: The aim was to determine and compare the short-term effects of two intensive semi-occluded vocal tract (SOVT) programs, "straw phonation" (SP) and "resonant voice therapy" (RVT), on the phonation of children with vocal fold nodules.

Method: A pretest-posttest randomized controlled study design was used. Thirty children aged 6-12 years were randomly assigned to the SP group ( = 11), RVT group ( = 11), or control group receiving indirect treatment ( = 8) for their voice problems.

View Article and Find Full Text PDF

Accurately predicting individual antidepressant treatment response could expedite the lengthy trial-and-error process of finding an effective treatment for major depressive disorder (MDD). We tested and compared machine learning-based methods that predict individual-level pharmacotherapeutic treatment response using cortical morphometry from multisite longitudinal cohorts. We conducted an international analysis of pooled data from six sites of the ENIGMA-MDD consortium (n = 262 MDD patients; age = 36.

View Article and Find Full Text PDF

While the direct health impacts of air pollution are widely discussed, its indirect effects, particularly during pandemics, are less explored. Utilizing detailed individual-level data from all designated hospitals in Wuhan during the initial COVID-19 outbreak, we examine the impact of air pollution exposure on treatment costs and health outcomes for COVID-19 patients. Our findings reveal that patients exposed more intensively to air pollution, identified by their residence in downwind areas of high-polluting enterprises, not only had worsened health outcomes but also consumed more medical resources.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!